Sunday 24 September 2017

Novartis gets short reprieve on drug patent loss

NOVARTIS, which employs about 1,200 people in Ireland, has improved its financial outlook for 2013 following a delay in its competitors' attempts to produce its best-selling blood pressure pill, granting the Swiss drugmaker a temporary reprieve from patent losses.

Novartis, the world's second-biggest drug maker, lost its patent rights on Diovan in the US last year and is now facing competition from a copycat version from Ranbaxy Laboratories. But that company has so far failed to get a green light in the US.

"This is good news, but only short term, as the sales impact is merely delayed into 2014," said Sarasin analyst David Kaegi.

Irish Independent

Also in Business